Oncology Australia, CAR-T therapy, and solid tumours Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.
News Lilly forges $3.35bn alliance with China's InnoCare Eli Lilly continues a busy period of deal-making with a five-project partnership with InnoCare that includes $100m in upfront and near-term payments.
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
News Akeso and CStone secure China clearances for next-generation... Hong Kong biopharma company Akeso has secured clinical trial clearance in China for a next-generation antibody-drug conjugate (ADC) targeting B7-H3.
News Sandoz adds 10 biosimilars through $322m Henlius deal Sandoz is set to add up to 10 new biosimilar assets to its portfolio under a new collaboration deal with China’s Shanghai Henlius Biotech.
R&D GLP-1 RAs in CKM management: A Q&A with CORXEL GLP-1 RA medicine has transformed treatment of metabolic diseases such as obesity and diabetes. We spoke with China's CORXEL about theirs.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.